Viatris (VTRS) SEC Filings

Viatris Inc. reported third-quarter 2026 revenue of $3.7495 billion, versus $3.7599 billion a year earlier, and a net loss of $325.3 million, compared with a $128.2 million loss. For the first nine months, revenue was $11.0233 billion versus $10.5963 billion, while net loss narrowed to $267.7 million from $3.1748 billion. Operating cash flow was $1.6695 billion, versus $1.5001 billion.

On October 8, Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Viatris commenced its tender offer on October 30; the offer and withdrawal rights expire November 16 unless extended or earlier terminated. The transaction is subject to customary closing conditions, including a majority of Pacira shares being tendered and expiration of the applicable regulatory waiting period, and is expected to close by the end of November 2026. Viatris expects to fund it primarily with excess cash and the remainder with short-term borrowings.

The board declared a quarterly $0.12-per-share dividend payable December 16 to shareholders of record November 23. During the first nine months, Viatris repurchased 18.3 million shares at a cost of approximately $300 million.

Viatris Inc. reported third-quarter 2026 revenue of $3.75 billion, essentially flat year over year, and a U.S. GAAP net loss of $325.3 million, versus $128.2 million a year earlier. Adjusted EBITDA was $1.20 billion, up 4% reported, and operating cash flow was $899.4 million, up 21%. Viatris raised the midpoints of all 2026 guidance ranges: revenue to $14.8 billion, Adjusted EBITDA to $4.50 billion, Adjusted EPS to $2.60 and free cash flow excluding transaction- and restructuring-related costs to $2.30 billion. The guidance ranges exclude Pacira's contribution and transaction- and restructuring-related costs.

Viatris agreed to acquire all outstanding Pacira common shares for $36.50 per share in cash, at an aggregate equity value of $1.65 billion; closing is expected by the end of November 2026. Through September 30, 2026, it returned approximately $717 million to shareholders, including approximately $300 million in repurchases. After an Official Action Indicated inspection classification, Viatris voluntarily suspended manufacturing at its Nashik, India facility in October and expects production to resume in the first quarter of 2027; supply constraints had an estimated $100 million revenue impact in the third quarter and are anticipated to have an approximately $100 million impact in the fourth quarter.

Viatris Inc. (VTRS) agreed to acquire Pacira BioSciences for an aggregate equity value of $1.65 billion, with cash consideration of $36.50 per Pacira share through a tender offer followed by a merger. The offer has not yet commenced. Closing conditions include valid tenders together with shares already owned by Purchaser and its affiliates representing at least one share more than 50% of Pacira’s outstanding shares, expiration or termination of the Hart-Scott-Rodino waiting period, and other customary conditions; the offer has no financing condition.

The offer is to remain open for 10 business days, subject to extension in certain circumstances. Pacira’s board unanimously recommends tendering; remaining eligible shares would receive the same consideration in the merger, and Pacira would become a wholly owned Viatris subsidiary. Viatris expects closing by the end of 2026 and said it expects the deal to be immediately accretive to its financial guidance metrics. Pacira reported approximately $746 million in revenue and $177 million in adjusted EBITDA for the 12 months ended June 30, 2026.

Viatris Inc (VTRS) director Leo Frans Groothuis was automatically granted 2,469 deferred stock units on September 30, 2026, in lieu of quarterly non-employee director fees in cash. The grant was based on Viatris common stock’s September 30 closing price of $17.72 per share; the reported total after the grant was 5,225 deferred stock units. The filing also lists 19.4313 dividend equivalent DSUs accrued on previously granted DSUs.

Viatris Inc director David S. Simmons was automatically granted 2,117 deferred stock units on September 30, 2026, in lieu of cash quarterly non-employee director fees, based on that day’s closing price of $17.72 per common share. His reported direct deferred-stock-unit balance after the grant was 4,479. A separate direct holding of 16.6533 dividend equivalent DSUs was also reported.

Viatris Inc (VTRS) received an amended Schedule 13G/A reporting that FMR LLC and Abigail P. Johnson collectively report beneficial ownership of 126,764,446.45 shares of Viatris common stock, representing 11.0% of the class as of August 31, 2026.

FMR LLC reports sole voting power over 113,359,609.44 shares and sole dispositive power over 126,764,446.45 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 126,764,446.45 shares and no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of Viatris’s outstanding common stock.

Viatris Inc (VTRS) reported that Chief Administrative and Transformation Officer Andrew Enrietti had restricted stock units (RSUs) and related dividend equivalent units (DEUs) granted on August 15, 2025 vest on August 15, 2026. On that date, 25,134 RSUs and 998.3636 DEUs were converted into common stock. To cover associated tax liabilities on the RSU and DEU settlements, 10,931 and 435 shares of common stock, respectively, were withheld at $16.23 per share. The filing notes that an additional 25,133 RSUs will vest on August 15, 2027 and 25,134 RSUs will vest on August 15, 2028, with DEUs vesting on the same schedule. The Rule 10b5-1 trading plan checkbox was left unchecked.

Davis Selected Advisers reports a significant ownership position in Viatris Inc common stock. The firm is the beneficial owner of 75,232,254 shares, representing 6.5% of the outstanding common stock.

Within this stake, Davis Selected Advisers has sole voting power over 72,567,897 shares, meaning it alone can vote or direct the voting of those shares. It also has sole dispositive power over all 75,232,254 shares, giving it the authority to dispose of or direct the disposition of the entire reported position. No shared voting or shared dispositive power is reported.

The filing identifies Davis Selected Advisers, organized in Colorado and based in Tucson, Arizona, as the reporting person, with the position reported in the common stock of Viatris Inc, CUSIP 92556V106.

Viatris reported Q2 2026 total revenues of $3,756.8 million, up from $3,582.1 million a year earlier, driven by strong brands such as Lipitor ($914.2 million), Norvasc, and other established products. Net sales for the first half of 2026 were $7,255.6 million versus $6,812.2 million in 2025.

The company posted a Q2 2026 net loss of $118.8 million (basic and diluted EPS $(0.10)), but for the first six months generated net earnings of $57.6 million, compared with a net loss of $3,046.6 million in the prior-year period, which had included a $2,936.8 million goodwill impairment. First-half operating cash flow was $770.1 million.

At June 30, 2026, Viatris held $886.5 million in cash and cash equivalents and long-term debt of $11,612.4 million, reflecting repayment of $1.675 billion 2026 Senior Notes and issuance of €650.0 million 4.250% Senior Notes due 2033 plus a new ¥40 billion term loan facility. The company continued returning capital via dividends of $0.12 per share each quarter and repurchased about 9.4 million shares for $150.0 million in the first half, bringing cumulative repurchases under its program to approximately 103.5 million shares for $1.15 billion as of June 30, 2026.